Immuno-gene therapy with interferon-β before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma  by Kruklitis, Robert J et al.
Immuno-gene therapy with interferon- before surgical
debulking delays recurrence and improves survival in a
murine model of malignant mesothelioma
Robert J. Kruklitis, MD, PhDa
Sunil Singhal, MDb
Peter Delong, MDa
Veena Kapoor, BSa
Daniel H. Sterman, MDa
Larry R. Kaiser, MDb
Steven M. Albelda, MDa
Objectives: Immuno-gene therapy of mesothelioma with an adenovirus encoding
interferon-mediated strong antitumor responses in murine models with low but not
high tumor burden. Our goals were to determine the mechanisms responsible for this
loss of efficacy and to test the hypothesis that the combination of preoperative
adenovirus encoding interferon- and surgical resection would be effective in
treating bulky tumors.
Methods: Flank tumors of a mouse mesothelioma cell line were treated with
adenovirus encoding interferon- or adenoviral vector encoding the bacterial pro-
tein -galactosidase. Cytotoxic T lymphocytes and tumor infiltration by T lympho-
cytes were measured. Tumors were surgically excised 72 hours later and tumor cells
were injected in the contralateral flank to create a model of a metastatic focus.
Tumor-free survival and distant metastatic disease were assessed.
Results: Immuno-gene therapy effectively treated small tumors (200 mm3) but did
not reduce the size of large (800 mm3) flank tumors. Although treatment with
adenovirus encoding interferon- resulted in the generation of tumor-neutralizing
splenocytes in large tumors, the number of T cells visualized within the tumors was
minimal. Tumors treated with adenovirus encoding interferon- (versus adenoviral
vector encoding the bacterial protein -galactosidase or phosphate-buffered saline
solution) prior to debulking increased long-term tumor-free survival and resulted in
two- to sixfold smaller foci of implanted tumor cells at 2 weeks postoperatively.
Conclusions: The use of adenovirus encoding interferon- or surgical debulking
alone is ineffective in treating large tumors, but combining preoperative adenovirus
encoding interferon- and surgical debulking significantly reduces tumor recurrence
and improves long-term tumor-free survival. We postulate that adenovirus encoding
interferon- amplifies the cytotoxic T-lymphocyte antitumor response, allowing
elimination of residual tumor cells.
One of the most intriguing but as yet unfulfilled approaches toantitumor treatment is immunotherapy. When successful, immu-notherapy stimulates endogenous antitumor immunity to the pointof eradicating established tumors. This treatment approach holdspromise for tumors such as malignant mesothelioma whose prog-nosis is otherwise dismal. Various interferons, interleukins, and
cytokines may stimulate antitumor immunity. Cytokines such as interleukin-2
(IL-2), GM-CSF, IL-12, interferon- (IFN-), and IFN- have been tried.1-5 How-
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ever, systemic administration of cytokines has resulted in
considerable toxicity in both human and murine models.4,6,7
The strategy of using viral gene transfer to directly intro-
duce various cytokines into tumor cells has thus been pro-
posed.5,8 This provides an increased local concentration of
cytokines while minimizing the systemic toxicities.
We have previously demonstrated that intraperitoneal
administration of an adenoviral vector encoding the cyto-
kine IFN- (Ad.IFN-) could cure early-stage malignant
mesothelioma in murine models.9,10 However, like most
immunotherapeutic strategies, efficacy was much lower in
animals with large tumor burdens.11-13
The objectives of this study were to determine why
immunotherapy with Ad.IFN- was ineffective against a
larger tumor burden and to assess the efficacy of combining
preoperative Ad.IFN- with surgical debulking. The role of
surgical debulking or cytoreductive surgery alone has been
controversial.14-18 Despite small increases in survival for
patients with advanced-stage disease, the majority of pa-
tients succumb to their disease, reinforcing the inadequacy
of cytoreduction. Treatment of malignant mesothelioma is
no exception. Surgical debulking, either alone or in combi-
nation with conventional chemo- or radiotherapy, has re-
sulted in only small survival benefit.19-21
Debulking surgery ultimately fails due to the small num-
bers of tumor cells that remain after resection. It is thus
logical to postulate that immuno-gene therapy, which can
effectively eradicate a small tumor burden, could be highly
effective when combined with cytoreductive surgery.11,22,23
We therefore tested the combination of Ad.IFN- immuno-
gene therapy before surgical debulking to treat large me-
sothelioma tumors in a syngeneic mouse model.
Materials and Methods
Cell Lines and Adenoviral Vectors
The mouse mesothelioma cell line AB12 and the Ad.IFN- have
been previously described.9 AB12 cells are an aggressive mouse
mesothelioma cell line generated by intraperitoneal injection of
asbestos. L1C2 cells are a bronchioalveolar cell line obtained from
American Type Culture Collection (Manassas, Va). A control
adenoviral vector encoding the bacterial protein -galactosidase
(Ad.LacZ) was obtained from the vector core at the University of
Pennsylvania Medical Center.
Experimental Animals
All experiments used immunocompetent female BALB/c mice
(6-8 weeks old; weight, 20-25 g) that were obtained from Tac-
onic Laboratory (Germantown, NY). The University of Pennsyl-
vania and the Animal Use Committees of the Wistar Institute
approved all protocols in compliance with the Guide for the Care
and Use of Laboratory Animals.
AB12 Flank Tumor Model
An AB12 flank tumor model was established to examine the
treatment efficacy of locally administered Ad.IFN-. AB12 cells
(5  105 in 100 L of serum-free Dulbecco’s modified Eagle’s
medium [DMEM]) were injected subcutaneously into the flanks of
BALB/c mice. Mice received a single intratumoral injection of
Ad.IFN- at a dose of 109 plaque forming units (pfu) at the designated
time or tumor volume. This dose is close to the maximally tolerated
dose and was chosen based on previous titration experiments.9 Tumor
volume was calculated by the following formula, where length is the
longest diameter and width is the diameter along the perpendicular
axis: Tumor volume (mm3)  (/6) · (Length) · (Width)2.
Control mice were treated in an analogous manner with injec-
tion of either 109 pfu Ad.LacZ virus or 100 L of phosphate-
buffered saline solution (PBS) as indicated. Animals were killed
when they met predetermined criteria established for minimizing
pain and suffering.
Winn Assay for the Detection of Tumor Neutralizing
Cells
Splenocytes were isolated from spleens (2 mice/group) that were
harvested 8 to 10 days after intratumoral treatment with Ad.IFN-
or control Ad.LacZ virus. The isolated splenocytes were purified
using lymphocyte isolation solution (Ficoll-Paque Plus; Amer-
sham Biosciences, Piscataway, NJ) and then suspended in serum-
free DMEM. In some experiments, the CD8 T cells were sepa-
rated from the total splenocyte pool using MACS isolation system
(CD8a [Ly-2] mouse MicroBeads; Miltenyi Biotec, Auburn,
Calif). The isolated cells consisted of greater than 90% CD8 T
cells as determined by fluorescence-activated cell sorter analysis.
The CD8 cell pool comprised those cells that did not adhere to
the column.
Fresh AB12 cells (or in some cases, L1C2 cells) were then
mixed with the splenocytes (Winn Assay24) in a ratio of 10
splenocytes to 1 AB12 tumor cell. The resulting mixture (100 L;
5  106 splenocytes and 5  105 AB12 cells) was injected
subcutaneously into the flanks of 5 naı¨ve BALB/c mice. A control
group of 5 mice with AB12 cells alone (5  105 in 100 L) were
injected in an analogous fashion. When CD8 T cells were used,
they were mixed with AB12 cells or L1C2 cells in a ratio of 3
CD8 cells to 1 AB12 cell as CD8 T cells make up about 30%
of the total splenocytes. In these experiments, the injected mixture
thus contained 1.5  106 CD8 T cells and 5  105 AB12 cells.
Tumor size was assessed over the next 14 days.
Immunohistochemistry
Dissected flank tumors were snap-frozen in Tissue-Tek ornithine
carbamoyltransferase (Sakura Finetek, Torrance, Calif), sectioned
at 4 m onto gelatin-coated slides, and fixed in cold acetone. We
performed immunoperoxidase staining by using the avidin-biotin-
peroxidase Vectastain Elite ABC kit (Vector Laboratories, Burlin-
game, Calif). Primary antibodies were mAbs anti-CD4 (GK 1.5)
and anti-CD8 (Ly-2) (Southern Biotechnology, Birmingham, Ala).
Debulking Surgery
Mice with flank tumors greater than 800 mm3 were anesthetized
and shaved. An incision 1 to 2 cm was made immediately adjacent
to the tumor. The mass was then completely excised using standard
blunt dissection. Occasionally it was necessary to remove skin that
was adherent to the tumor. If the tumor was found to be extending
through the abdominal wall, the mouse was excluded as debulking
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was not possible (less than 5% of mice). Skin closure was performed
using sterile 3-0 sutures. Preoperative treatment was unknown to the
investigator performing surgery and making tumor measurements.
Tumor Rechallenge in Mice Treated with Neoadjuvant
Ad.IFN-
At the time of tumor debulking, animals from the above experi-
ments were rechallenged in the contralateral flank with subcuta-
neous injections of 5  105 cells of AB12 cells in 100 L of
serum-free DMEM.
Statistical Analysis
Tumor volumes are reported throughout the text as mean tumor
volume. We analyzed differences by Student t test (2 groups) or
1-way analysis of variance (ANOVA) for multiple comparisons
with appropriate post hoc testing. Fisher exact test was used for
categorical data. Survival was calculated from the date of surgery.
Results are expressed as mean  standard error of the mean.
Results
Immuno-Gene Therapy Loses Efficacy as Tumor
Burden Increases
AB12 mesothelioma tumors were established in the flanks
of BALB/c mice. After 4, 7, or 14 days, mice were injected
intratumorally with Ad.IFN-. The average tumor volumes
at the time of injection were 111 63 mm3, 293 75 mm3,
and 929  89 mm3 at days 4, 7, and 14, respectively.
As shown in Figure 1, the efficacy of Ad.IFN- de-
pended on the tumor size at time of treatment. Treatment of
tumors at day 4 and day 7 led to statistically significant
decreases in tumor size versus control at day 31 (P  .001);
administration of Ad.IFN- to small tumors (200 mm3)
typically resulted in complete response. Greater than 80% of
the mice remained disease-free for more than 45 days fol-
lowing treatment. In contrast, administration of Ad.IFN-
to larger tumors (200-800 mm3) was less effective. When
tumor volume exceeded 800 mm3, Ad.IFN- administration
had no statistically significant effect on tumor growth.
These findings demonstrate that the benefit of immuno-gene
therapy diminishes as tumor burden increases.
Ad.IFN- Therapy Stimulates a Cellular Antitumor
Response Independent of Tumor Size
Animals with small (75-200 mm3) and large AB12 flank
tumors (800-1200 mm3) had their splenocytes harvested,
mixed with viable tumor cells, and then injected into naı¨ve
mice. As shown in Figure 2, A, splenocytes from animals
bearing small tumors significantly (P  .05) inhibited the
growth of new tumors. In contrast, splenocytes from ani-
mals bearing large tumors had no significant effect on tumor
growth (382  37 mm3 in small tumors vs 814  43 mm3
in large tumors, P  .05, at 12 days).
The effect of Ad.IFN- treatment on the generation of
tumor-killing splenocytes in animals with large tumors was
then assessed. As shown in Figure 2, B, the splenocytes
from the Ad.IFN-–treated-mice inhibited tumor growth to
a greater degree than the splenocytes from the Ad.LacZ-
Figure 1. Ad.IFN- therapy loses efficacy as tumor burden increases. AB12 mouse mesothelioma tumors were
treated with Ad.IFN- on days 4, 7, or 14 following inoculation. The control group was injected with PBS on day
4. Experiments were repeated on 3 occasions with similar results (5 mice in each group/replicate).
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treated mice (81  75 mm3 vs 437  37 mm3, P  .05, at
7 days). This tumor-neutralizing capability was specific for
AB12 tumor cells; splenocytes from Ad.IFN-–treated
mice did not inhibit the growth of L1C2 lung adenocarci-
noma tumors (Figure 2, C).
To determine which cells were responsible for this anti-
tumor effect, we isolated CD8 T cells. Similar to our data
with total splenocytes, the rate of tumor development in
mice injected with the mixture of tumor cells and CD8 T
lymphocytes isolated from Ad.IFN--treated mice was sig-
nificantly less than in those treated with Ad.LacZ (120 18
mm3 vs 388 35 mm3, P .01, at 7 days; Figure 2, D). Thus,
cytotoxic T lymphocytes (CTLs) are generated after injection
of Ad.IFN- into mice with large tumor burdens; however, as
shown in Figure 1, these CD8 cells are not able to effectively
alter tumor progression in animals with bulkier tumors.
Inadequate CTL Tumor Infiltration Contributes to
Failure of Immuno-Gene Therapy in Large Tumors
We examined both small and large flank tumors, treated
either with Ad.IFN- or control, using immunohistochem-
istry. Eight days following viral injection, tumor-bearing
mice were killed and the flank tumors harvested and stained.
As shown in the top panel in Figure 3, Ad.LacZ-injected
(control) tumors had very few CD4 or CD8 T cells
within the core of small tumor nodules. However, intratu-
moral injection of Ad.IFN- into small tumors resulted in a
clear increase in the number of infiltrating CD4 and CD8
T cells (Figure 3, upper panel). In contrast, in animals
bearing large tumors, Ad.IFN- treatment did not lead to
increased numbers of infiltrating CD4 or CD8 T cells
(Figure 3, bottom panel). These data support the hypothesis
that the lack of efficacy of Ad.IFN- therapy in bulkier
Figure 2. Assessment for tumor-neutralizing cells using the Winn Assay. A, Splenocytes were isolated from mice
bearing either small (75-200 mm3) or large (800-1100 mm3) AB12 flank tumors and mixed with fresh AB12 tumor cells.
Each mixture was injected into naı¨ve mice and tumor volumes were measured on day 7. B, Splenocytes from large
(800-1100 mm3) flank tumors that had been treated with either Ad.IFN- or Ad.LacZ were isolated and mixed with AB12
tumor cells or (C) with L1C2 lung cancer cells. Each mixture was injected into naı¨ve mice and tumor volume measured
on day 7. D, Similar studies in animals with large flank tumors treated with either Ad.IFN- or Ad.LacZ were performed
using purified CD8 T cells mixed with AB12 tumor cells. *P < .01 compared with both other groups.
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tumors is due, at least in part, to the inability of CD4 and
CD8 T cells to infiltrate into or persist in bulky tumors.
Addition of Preoperative Viral Gene Therapy to
Surgical Debulking Provides More Effective Therapy
of Large Tumors
Because Ad.IFN- injection of large tumors induced
splenocytes and CD8 T cells with antitumor activity, we
reasoned that removal of the large tumor mass might allow
these immunocytes to effectively kill small amounts of
residual tumor. Large flank tumors (800 mm3) were thus
treated with either Ad.IFN- (n  5) or Ad.LacZ (n  5).
Three days later, the tumors were excised. This experimen-
tal design allowed direct injection of a large number of
tumor cells that would not be possible with perioperative or
postoperative injection. As shown in Figure 4, A (results
from 1 experiment), pretreatment of the tumors with
Ad.IFN- led to a significant (P  .01) increase in the
number of animals that remained tumor-free. In 4 replicate
experiments, treatment with Ad.IFN- (n  34) versus
Ad.LacZ (n  10) or PBS (n  18) prior to surgical
debulking resulted in a delay of local tumor recurrence
(mean recurrence time: 19 days vs 6 days, P  .01) and an
increase in 25-day disease-free survival (58% vs 11%, P 
.01; Table 1).
To further test the benefits of surgical debulking, viable
AB12 tumor cells were injected into the contralateral flank
at the time of operation to model a focus of unresected
metastatic disease. Although tumors ultimately developed,
the tumors were significantly smaller on both day 17 (P 
.05) and day 25 (P  .05) with neoadjuvant Ad.IFN-
compared with debulking alone (Figure 4, B).
Discussion
Malignant mesothelioma is an aggressive tumor of serosal
surfaces (pleura, pericardium, peritoneum) that is highly
associated with asbestos exposure. Despite aggressive ther-
apy including surgical resection, chemotherapy, and radia-
tion therapy, the median life expectancy is still 12 to 16
Figure 3. CD4 and CD8 T lymphocytes infiltrate small but not large tumors following Ad.IFN- treatment. Mice
bearing small (75-200 mm3) (upper panel) and large (800-1100 mm3) (lower panel) flank tumors were treated with
Ad.LacZ and Ad.IFN-. Flank tumors were harvested, sectioned, and stained for CD4 and CD8 T cells 8 days
following treatment.
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months from time of diagnosis.19 Therefore, novel treat-
ment approaches, such as immunotherapy, are desperately
needed for this devastating disease.
We have previously shown that Ad.IFN- was highly
effective in treating small but established tumors in a mouse
intraperitoneal mesothelioma model.9,10 Unfortunately, in
our animal studies, the efficacy of Ad.IFN- immunother-
apy was greatly diminished with increasing tumor burden.
There are a number of reasons to account for the lack of
efficacy of immunotherapy against large tumor burdens. We
have demonstrated that although cytotoxic T lymphocytes
are generated after treatment of large tumors with
Ad.IFN-, they fail to effectively traffic into or persist in
established large tumors. Continued tumor growth may sim-
ply be a reflection of ineffective CTL trafficking. Alterna-
tively, other mechanisms, which have yet to be defined,
might contribute to the diminished antitumor efficacy. For
instance, the generated CTLs may simply be outnumbered
by the vast quantities of viable tumor cells in bulky tumors,
thus making tumor destruction impossible. Another factor
may be the altered vascularity within a large tumor mass.24
It is also probable that an immunosuppressive environment
exists within bulky tumors.11,22 It has been demonstrated
that both tumor cells and infiltrating cells (immature my-
eloid cells, T-regulatory cells, suppressive macrophages)
elaborate immunosuppressive factors such as prostaglandin
E2, tumor growth factor (TGF)-, IL-10, and vascular en-
dothelial growth factor in bulky tumors.12,25 These immu-
nosuppressive factors can inhibit CTL trafficking and in-
duce apoptosis of antitumor cells that enter the tumor. 24
Strategies to Overcome the Immunosuppression of
Large Tumors
Various strategies have been used to decrease the immuno-
suppressive environment in large tumors. We have prelim-
inary data that cyclooxygenase-2 inhibitors are effective by
decreasing the formation of prostaglandin E2 and IL-10.
Other approaches such as neutralization of TGF-26 using
either antisense or monoclonal antibodies or removal of
T-regulatory cells by depletion with anti-CD25 antibodies27
have also shown promising results.
We opted to test a different approach. We reasoned that
debulking surgery would both decrease the number of via-
ble tumor cells (improving the antitumor CD8 to tumor
cell ratio) and greatly diminish the production of immuno-
suppressive cytokines. This would allow the CTLs gener-
ated by Ad.IFN- therapy to more effectively kill any
Figure 4. Neoadjuvant Ad.IFN- delays tumor recurrence and
prolongs tumor free survival. A, Large AB12 flank tumors (800-1000
mm3) were treated with Ad.IFN- (squares) or PBS (circles).
Three days following treatment the tumors were surgically de-
bulked. Mice were followed for local recurrence. The percent of
mice tumor-free versus time after surgery is plotted. B, Growth of
metastatic foci was measured. *P < .01 compared with surgery
alone. Note: Each experimental group contained 5 mice; all
experiments were repeated in triplicate with similar results.
TABLE 1. Neoadjuvant Ad.IFN- therapy decreases recur-
rence rate following debulking surgery
Neoadjuvant Ad.IFN-
(cured:treated)
Ad.LacZ/PBS control
(cured:treated)
4:4 0:3
3:10 0:10
4:5 1:5
5:10 0:5
4:5 2:5
Total cured: 20:34 (58%)* Total cured: 3:28 (11%)*
Ad.IFN-, Adenoviral vector encoding the cytokine interferon-; Ad.LacZ,
adenoviral vector encoding the bacterial protein -galactosidase; PBS,
phosphate-buffered saline solution.
A series of individual experiments were performed in which mice with
large flank tumors (800 –1500 mm3) were treated with neoadjuvant
Ad.IFN- or control (Ad.LacZ or PBS). Subsequently tumors were surgi-
cally excised. The data denotes the ratio of “cured” animals (defined as
tumor-free for 25 days following surgical debulking) to the total number of
animals treated. The percentage of animals “cured” after neoadjuvant
Ad.IFN- was significantly higher (P  .001; chi-square) than control
animals.
*58% versus 11%, P  .001, chi-square analysis.
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remaining tumor cells. Furthermore, there are data to sup-
port the idea that debulking surgery might augment antitu-
mor immune responses. Specifically, tumor resection might
unmask a population of primed T cells able to mediate
protective immunity.13 Additionally, resection has been
shown to enhance the immune response by reducing nega-
tive immune modulators and suppressors of local immune
response,28 restoring colony growth inhibition29 and pre-
venting immunological overburdening.30
Surgical debulking alone in our animal model was
largely ineffective. Likewise, immuno-gene therapy alone
was ineffective with increased tumor burden. However, the
combination of immuno-gene therapy followed by surgical
debulking was much more effective at treating mice with
large tumors. These results are consistent with previous
work showing that neoadjuvant therapy with IL-12–loaded
polylactic acid microspheres reduced local recurrence and
distant metastases.22,23
We suggest that intratumoral injection of Ad.IFN- trig-
gers an antitumor immune response that is mediated via
CD8 CTLs. Although ineffective against large tumors, this
immune response is capable of controlling the residual
disease that is undoubtedly left behind following debulking
surgery. We postulate that by giving Ad.IFN- preopera-
tively, the immune system is primed to eliminate residual
tumor cells before these cells have a chance to repopulate.
Potential Limitations
Admittedly, there are some limitations to this animal model.
Although mesothelioma is predominately an intrapleural
and intraperitoneal disease, we have studied flank tumors in
mice. This model allowed us to readily monitor tumor
burden, perform complete tumor resections, and assess for
recurrent disease. It is not yet known for certain how these
findings will translate to an intracavitary tumor model.
In these studies, we utilized an adenovirus expressing
murine interferon- in murine mesothelioma cell lines be-
cause immune responses are the key to our therapeutic
effects. We were unable to use human mesothelioma cell
lines as they can only be grown in immunodeficient animals.
Some biological differences between the response of tumor
cells to murine and human interferons may exist. For ex-
ample, there is some data to suggest that there may be a
greater direct cytotoxic effect with human IFN-, perhaps
suggesting that it could be even more efficacious than
murine IFN-.
The optimal timing of immunotherapy in relation to
surgical debulking also remains to be determined. In our
experiments, we administered immunotherapy prior to sur-
gical resection, allowing sufficient time to generate an an-
titumor immune response. Alternative approaches, such as
administration of immunotherapy into the tumor bed at the
time of resection or following resection, were difficult to
assess in our model but may be possible in clinical scenar-
ios.
With these caveats in mind, we suggest that the strategy
of administering immunotherapy followed by surgical re-
section may provide a technique to optimize immuno-gene
therapy in clinical practice.
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Discussion
Dr G. Alexander Patterson (St Louis, Mo). As I understand it, the
adenoviral vector injection was made into the tumor cells (ie,
directly into the tumor mass)?
Dr Singhal. Right.
Dr Patterson. Why would you have to do that? Why not, for
example, utilize an intramuscular injection or an intravenous in-
jection? Why do you have to put it in the tumor?
Dr Singhal. Dr Patterson, thank you for your question. Intra-
tumoral delivery of gene therapy is designed to minimize systemic
toxicity. The idea is that transduced tumor cells will express high
levels of interferon- in the local tumor environment only. This
approach minimizes toxicity of the vectors. Furthermore, we have
found that to establish the maximal antitumor immune response,
we need to transduce tumor cells with Ad.IFN-. This is probably
due to the expression of high local concentrations of interferon-
in conjunction with tumor antigens.
Dr Bryan Meyers (St Louis, Mo). Could you just elaborate on
how you came upon the 3 days as the lead time between the
injection and the surgery? It seems like maybe longer would be
better. I can see that any shorter might not be enough time, but how
did you come upon 3 days?
Dr Singhal. One goal of our experiments is to determine the
optimal timing for the immunogene therapy. We are trying to
determine when the CD8 T-cell population is maximized by
Ad.IFN- therapy so residual tumor cells cannot implant. We have
tried giving Ad.IFN- at the time of surgery, 3 days before, 7 days
before, and 10 days before surgery. Each time we performed a
Winn assay, which is a technique we utilized to detect antitumor
cells. So far our data has demonstrated that 3 days before surgery
is the best time to treat the mice. Whether this will translate to
humans is not clear.
Dr Frank W. Sellke (Boston, Mass). How long does this
memory last where you give the interferon and you get the in-
creased level of CD8 cells so that it does prevent tumor recur-
rence?
Dr Singhal. We have challenged “cured” mice with viable
tumor cells up to 30 days following their resection. The mice that
were cured with Ad.IFN- followed by surgical resection com-
pletely resisted rechallenge. In contrast, the rare mice cured with
surgical resection alone were not protected from rechallenge. No
time points greater than 30 days were assessed.
Dr Sellke. How long does the effect last? You resected the
tumor, yet you have a beneficial effect on reinjecting more tumor
cells, is that correct?
Dr Singhal. When we rechallenge the mice with tumor cells,
we inject the tumor cells either the day of or the next day. I don’t
think the Ad.IFN-–transduced tumor cells actually last very long.
I think that due to the innate immune system, the T cells come back
and attack transduced cells, which are now recognized as foreign.
However, we have followed them as far as 60 days and have had
no recurrence.
Now, we have taken a subset of mice in 1 of the 5 experiments.
We challenged them at 30 days. In that case, we still had a twofold
smaller tumor burden in mice that did recur. It is important to note
that all the mice do recur. They just grow back at a slower rate. It
is not that if there are 20 mice in the experiment, 3 mice grow back
and 17 do not grow back. They all eventually do recur, but they
recur at a much slower rate. This allows us to consider other
interventions.
Dr Sellke. Can you readminister the gene therapy or is there
some downside to giving it several times? Could you give the gene
therapy, say, every month or 2 to slow the recurrence further?
Dr Singhal. We have not done it, but I suspect it would not
work for 1 reason. I think we would develop an immune response
to the virus. I suspect it is a 1- or 2-shot deal. After the second
treatment, you probably get a strong immune response to the actual
adenoviral vector and probably would not get good transduction of
tumor cells.
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